Monoclonal Antibody to Neprilysin (CD10)
NEP; MME; CALLA; SFE; Atriopeptidase; Enkephalinase; Skin fibroblast elastase; Common Acute Lymphoblastic Leukemia Antigen; Membrane Metallo-Endopeptidase
- Product No.MAB785Hu23
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- SourceMonoclonal antibody preparation
- HostMouse
- Potency (Clone Number)C14
- Ig Isotype IgG1 Kappa
- PurificationProtein A + Protein G affinity chromatography
- LabelNone
- Immunogen RPB785Hu02-Recombinant Neprilysin (CD10)
- Buffer Formulation0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
- TraitsLiquid
- Concentration1mg/mL
- Organism Species MoreSus scrofa; Porcine (Pig)
- ApplicationsWB; IHC; ICC; IP.
If the antibody is used in flow cytometry, please check FCM antibodies. - DownloadInstruction Manual
- UOM 20µl100µl 200µl 1ml 10ml
- FOB
US$ 109
For more details, please contact local distributors! US$ 253 US$ 362 US$ 905 US$ 3620
SPECIFITY
The antibody is a mouse monoclonal antibody raised against CD10. It has been selected for its ability to recognize CD10 in immunohistochemical staining and western blotting.
USAGE
Western blotting: 0.5-2µg/mL
Immunohistochemistry: 5-20µg/mL
Immunocytochemistry: 5-20µg/mL
Optimal working dilutions must be determined by end user.
STORAGE
Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.
STABILITY
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
GIVEAWAYS
INCREMENT SERVICES
- Antibody Labeling Customized Service
- Protein A/G Purification Column
- Staining Solution for Cells and Tissue
- Positive Control for Antibody
- Tissue/Sections Customized Service
- Phosphorylated Antibody Customized Service
- Western Blot (WB) Experiment Service
- Immunohistochemistry (IHC) Experiment Service
- Immunocytochemistry (ICC) Experiment Service
- Flow Cytometry (FCM) Experiment Service
- Immunoprecipitation (IP) Experiment Service
- Immunofluorescence (IF) Experiment Service
- Buffer
- DAB Chromogen Kit
- SABC Kit
- Long-arm Biotin Labeling Kit
- Real Time PCR Experimental Service
Magazine | Citations |
13 | Elevated Plasma levels of Neutral Endpeptidase in Hypertension Patients Treated with Angiotensin Converting Enzyme Inhibitors Ahajournals:Source |
Biol Pharm Bull | Effect of High Glucose Levels on Amyloid β Production in Retinas of Spontaneous Diabetes Mellitus Otsuka Long-Evans Tokushima Fatty Rats PubMed: 25832640 |
Eur J Heart Fail. | Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction Pubmed:26725876 |
8 | A Test in Context: Neprilysin: Function, Inhibition, and Biomarker. pubmed:27491909 |
European Journal of Heart Failure | Effects of sacubitril/valsartan on neprilysin targets and the metabolism of natriuretic peptides in chronic heart failure: a mechanistic clinical study Pubmed: 30520545 |
European Journal of Heart Failure | Increased granulocyte membrane neprilysin (CD10) expression is associated with better prognosis in heart failure Pubmed: 30828920 |
Clinical Research in Cardiology | Soluble neprilysin, NT-proBNP, and growth differentiation factor-15 as biomarkers for heart failure in dialysis patients (SONGBIRD) Pubmed: 32002632 |
Neurotoxicology | Involvement of hippocampal agmatine in β1-42 amyloid induced memory impairment, neuroinflammation and BDNF signaling disruption in mice Pubmed: 32522471 |
European Heart Journal | P1620 Association of granulocyte neprilysin (CD10) expression with prognosis in heart failure with reduced ejection fraction |
Clin Biochem | Finding a reliable assay for soluble neprilysin Pubmed:35331754 |
Scientific Reports | The potential role of serum tau protein (MAPT), neuronal cell adhesion molecule (NrCAM) and neprilysin (NEP) in neurodegenerative disorders development in … |